Standing department
The Register
Six terms tracked across the federal publication archive: how many documents mention each, how they divide by document type, and what was published most recently. Retrieved 2026-10-13.
Remit
The Register runs in every issue. Its job is unglamorous: to keep a dated count of how much the federal publication record has to say about each of a small number of terms, and to show what it has said most recently.
Four of the six terms describe the compounding channel. One is the category’s defining compound, carried so that the contrast between the two is visible rather than asserted. One is the word peptide itself, carried as a ceiling figure and not as a measure of regulatory attention, because a full-text mention in a proposed rule about laboratory proficiency testing counts exactly the same here as a document about this sector.
Counts are cumulative across the whole archive rather than annual, and they count documents rather than obligations in force. The reasoning, and what the type split does and does not support, is in the issue’s second feature.
Documents per term, by type
Counts are cumulative across the whole published archive and count documents rather than obligations in force. A document matches on a full-text mention, so a passing reference counts the same as a document about the subject. Where the three type counts do not sum to the term total, the register classifies the remainder outside those three types and the shortfall is shown rather than absorbed.
| Term as queried | Documents | Final rules | Proposed rules | Notices | Other types | Query |
|---|---|---|---|---|---|---|
| Compounded drug | 124 | 17 | 21 | 86 | 0 | Re-run |
| Section 503A | 283 | 49 | 37 | 191 | 6 | Re-run |
| Outsourcing facility | 136 | 6 | 7 | 123 | 0 | Re-run |
| Bulk drug substances | 130 | 10 | 20 | 98 | 2 | Re-run |
| Peptide | 951 | 93 | 71 | 753 | 34 | Re-run |
| Semaglutide | 14 | 0 | 1 | 13 | 0 | Re-run |
Most recently published, per term
- Compounded drug
- Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment RequestNotice · 2026-08-28
- Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit ProgramProposed Rule · 2026-06-16
- Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic ActNotice · 2026-05-26
- Section 503A
- Request for Nominations for Individuals and Consumer Organizations for Advisory CommitteesNotice · 2026-10-01
- Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates; Guidance for Industry; AvailabilityNotice · 2026-09-09
- Agency Information Collection Activities; Announcement of Office of Management and Budget ApprovalsNotice · 2026-08-17
- Outsourcing facility
- Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act and Associated FeesNotice · 2026-08-31
- Outsourcing Facility Fee Rates for Fiscal Year 2027Notice · 2026-07-30
- Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic ActNotice · 2026-05-26
- Bulk drug substances
- Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act and Associated FeesNotice · 2026-08-31
- Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment RequestNotice · 2026-08-28
- List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment PeriodNotice · 2026-06-26
- Peptide
- Clinical Laboratory Improvement Amendments of 1988 (CLIA); Virtual Access, Gynecologic Cytology Proficiency Testing (PT), Personnel Qualifications, and Other ChangesProposed Rule · 2026-10-08
- Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production Activity; Merck, Sharp & Dohme LLC; (Drug Products and Intermediates); Rahway, New JerseyNotice · 2026-09-24
- Agency Information Collection Activities: Proposed Collection; Comment RequestNotice · 2026-09-17
- Semaglutide
- Product-Specific Guidances; Revised Draft Guidances for Industry; AvailabilityNotice · 2026-07-29
- List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment PeriodNotice · 2026-06-26
- List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic ActNotice · 2026-05-01
Sources, and the queries that produced every figure above
- Federal Register API, version 1, documents endpoint. Office of the Federal Register, National Archives and Records Administration. Retrieved 2026-10-13. One full-text term query per tracked term, then one count query per document type for the same term. Counts cover the whole published archive, not a single year.https://www.federalregister.gov/api/v1/documents.json?conditions[term]=<term>&per_page=5&order=newest